About this Research Topic
Regenerative medicine and associated technologies have evolved rapidly over the past couple of decades. Regenerative technologies have made a significant impact in both basic research and pharmaceutical and clinical applications. Some of the major efforts have been approved by the US Food and Drug Administration (FDA) and disseminated to clinical settings. With the development and advancement of cutting-edge translational technologies such as organ-on-a-chip, organoid systems, and 3D bioprinting, we are getting closer to pursue precision and personalized regenerative medicine. However, there are still scientific, technical, and regulatory hurdles in regenerative medicine that we should cut through to accelerate the translation of regenerative technologies in clinical setups.
We aim to discuss a broad spectrum of research efforts and breakthroughs in regenerative technologies. Primary research themes include but are not limited to stem cell engineering, tissue engineering, organ-on-a-chip, 3D bioprinting, organoid, biomaterials, biomechanics, and mechanobiology. We envision that this collection will address current challenges and potential breakthroughs for the development of in vitro organ models, disease simulation and its mechanistic studies, and validation of pharmaceuticals and biotherapeutics. Research topics that cover the development of new tissue constructs, tissue repair models, application and validation of current regenerative technologies in vivo or in a clinical setup, and advances in regenerative technology policy and regulations are also pertinent to discuss.
In this Research Topic, we will collect high-quality, high-impact articles that will be published by early-career investigators (within 10 years after completing their Ph.D., M.D., or other equivalent terminal degrees or 7 years since starting an independent Principal Investigator position). We accept Original Research articles as well as other types of articles (e.g., Review, Methods, Perspective) that discover basic science, technical advancement, and application of regenerative medicine and relevant technologies.
----
Hyun Jung Kim currently receives a research grant from GlaxoSmithKline. All other Topic Editors declare no conflicts of interest.
We aim to discuss a broad spectrum of research efforts and breakthroughs in regenerative technologies. Primary research themes include but are not limited to stem cell engineering, tissue engineering, organ-on-a-chip, 3D bioprinting, organoid, biomaterials, biomechanics, and mechanobiology. We envision that this collection will address current challenges and potential breakthroughs for the development of in vitro organ models, disease simulation and its mechanistic studies, and validation of pharmaceuticals and biotherapeutics. Research topics that cover the development of new tissue constructs, tissue repair models, application and validation of current regenerative technologies in vivo or in a clinical setup, and advances in regenerative technology policy and regulations are also pertinent to discuss.
In this Research Topic, we will collect high-quality, high-impact articles that will be published by early-career investigators (within 10 years after completing their Ph.D., M.D., or other equivalent terminal degrees or 7 years since starting an independent Principal Investigator position). We accept Original Research articles as well as other types of articles (e.g., Review, Methods, Perspective) that discover basic science, technical advancement, and application of regenerative medicine and relevant technologies.
----
Hyun Jung Kim currently receives a research grant from GlaxoSmithKline. All other Topic Editors declare no conflicts of interest.
Keywords: Regenerative medicine, Stem cell engineering, Tissue engineering, Organ-on-a-chip, 3D bioprinting, Organoid Biomaterials, Biomechanics and mechanobiology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
